

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 December 2021 (02.12.2021)



(10) International Publication Number
WO 2021/239077 A1

(51) International Patent Classification:

C07D 473/32 (2006.01) A61K 31/437 (2006.01)
C07D 487/04 (2006.01) A61P 35/00 (2006.01)
C07D 471/04 (2006.01) A61P 35/02 (2006.01)
A61K 31/52 (2006.01) A61P 9/12 (2006.01)
A61K 31/53 (2006.01) A61P 11/00 (2006.01)

(21) International Application Number:

PCT/CN2021/096539

(22) International Filing Date:

27 May 2021 (27.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/092801

28 May 2020 (28.05.2020)

CN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventor; and

(71) Applicant (for SC only): **GAO, Zhenting** [CN/CN]; Room
301, Building 147, No. 3468 Human Road, Pudong District,
Shanghai 201318 (CN).

(72) Inventors: **GUO, Haibing**; Apt. 2103, Building 4, 587
Nong, Laoshan Street, Pudong District, Shanghai 200135
(CN). **LI, Ming**; Room 101, No. 3, Lane 680, Dongjian
Road, Shanghai 201204 (CN). **LIU, Kevin Kun Chin**; Chi-
na Novartis Institutes For BioMedical Research, 4218 Jinke
Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shang-
hai 201203 (CN). **LU, Chunliang**; 167 Xi Jiang Wan Road,
Building 9, Ste. 602, Shanghai 200083 (CN). **SUN, Zhum-
ing**; Room 1402, 39 Nong, Qingtong Road, Pudong New
District, Shanghai 201203 (CN). **ZHU, Yihui**; 29 Deer-
wood Trail, Warren, New Jersey 07059 (US).

(74) Agent: **BEIJING HAN KUN LAW OFFICES**; 9/F, Of-
fice Tower C1, Oriental Plaza, 1 East Chang An Avenue,
Dongcheng District, Beijing 100738 (CN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: MLL1 INHIBITORS AND ANTI-CANCER AGENTS

(57) Abstract: The present invention provides a compound of Formula (I); or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL1).



(I)

WO 2021/239077 A1